KR102458937B1 - Method for producing red ginseng with improved active ingredients and yield - Google Patents
Method for producing red ginseng with improved active ingredients and yield Download PDFInfo
- Publication number
- KR102458937B1 KR102458937B1 KR1020220087351A KR20220087351A KR102458937B1 KR 102458937 B1 KR102458937 B1 KR 102458937B1 KR 1020220087351 A KR1020220087351 A KR 1020220087351A KR 20220087351 A KR20220087351 A KR 20220087351A KR 102458937 B1 KR102458937 B1 KR 102458937B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- aging
- fresh ginseng
- red ginseng
- steaming
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 50
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title description 20
- 230000032683 aging Effects 0.000 claims abstract description 31
- 238000010025 steaming Methods 0.000 claims abstract description 31
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 238000001035 drying Methods 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims description 77
- 241000208340 Araliaceae Species 0.000 claims description 76
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 75
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 75
- 241000913828 Apios Species 0.000 claims description 10
- 238000007602 hot air drying Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 8
- 235000020688 green tea extract Nutrition 0.000 claims description 7
- 229940094952 green tea extract Drugs 0.000 claims description 7
- 229940013712 pineapple extract Drugs 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims 1
- 229930182494 ginsenoside Natural products 0.000 abstract description 12
- 229940089161 ginsenoside Drugs 0.000 abstract description 10
- 230000002950 deficient Effects 0.000 abstract description 5
- 229930182490 saponin Natural products 0.000 description 15
- 235000017709 saponins Nutrition 0.000 description 15
- 150000007949 saponins Chemical class 0.000 description 15
- 239000007921 spray Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 6
- 230000005070 ripening Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 5
- 235000007119 Ananas comosus Nutrition 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000234671 Ananas Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 235000011201 Ginkgo Nutrition 0.000 description 3
- 241000218628 Ginkgo Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- KWDWBAISZWOAHD-MHOSXIPRSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]o Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KWDWBAISZWOAHD-MHOSXIPRSA-N 0.000 description 2
- FMIMFCRXYXVFTA-FUAOEXFOSA-N (4as,6ar,6as,6br,8ar,12ar,14bs)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1h-picene-4a-carboxylic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C FMIMFCRXYXVFTA-FUAOEXFOSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000003276 Apios tuberosa Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- ZUXNULGHCOXCFL-UHFFFAOYSA-N 2-(4-tert-butyl-2,6-dimethylphenyl)acetonitrile Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC#N ZUXNULGHCOXCFL-UHFFFAOYSA-N 0.000 description 1
- FMIMFCRXYXVFTA-UHFFFAOYSA-N 3-Oxo-12-oleanen-28-oic acid Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C FMIMFCRXYXVFTA-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 244000176051 Apios tuberosa Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 235000018122 Helianthus giganteus Nutrition 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000775685 Orogenia linearifolia Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- -1 Rg3 Chemical class 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- FFDHYUFECJTEAY-UHFFFAOYSA-N epimacherinic acid Natural products CC1(C)CCC2(CCC3(C)C(CCC4C5(C)CCCC(C)(C)C5CCC34C)C2C1)C(=O)O FFDHYUFECJTEAY-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 유효성분 및 수율이 개선된 홍삼의 제조방법에 관한 것으로써, 특히 혼합 숙성액을 이용하여 홍삼의 제조에 필요한 증숙 및 건조 시간을 단축시키는 동시에 불량 홍삼을 줄여 수율을 높이고 유효성분인 진세노사이드의 함량을 증가시킨 유효성분 및 수율이 개선된 홍삼의 제조방법에 관한 것이다. The present invention relates to a method for producing red ginseng with improved active ingredients and yield, particularly by using a mixed aged liquid to shorten the steaming and drying time required for the production of red ginseng, and at the same time reduce defective red ginseng to increase the yield and increase the yield of ginseng as an active ingredient It relates to an active ingredient with an increased content of senosides and a method for producing red ginseng with improved yield.
인삼(Panax ginseng C.A.Meyer)은 각종 질병의 예방과 치료에 탁월한 효과를 나타낼 뿐만 아니라 전혀 병이 없는 사람들에게도 힘과 활력을 주는 강장제로서 광범위한 약효를 나타낸다. 또한 장기간 사용하여도 전혀 부작용이 없다고 알려져 있어 한약 중에서도 최고의 약재로 꼽힌다.Ginseng (Panax ginseng C.A. Meyer) not only shows an excellent effect in the prevention and treatment of various diseases, but also shows a wide range of medicinal effects as a tonic that gives strength and vitality even to people without any disease. In addition, it is known to have no side effects even after long-term use, so it is considered as the best herbal medicine among herbal medicines.
밭에서 캔 그 상태로서의 인삼은 수삼이라 하며, 수삼은 70% 내외의 수분을 함유하고 있으므로 저장 또는 유통 과정에서 손상되기 쉽기 때문에 가공에 의해 저장성을 향상시킨다. 인삼은 가공방법에 따라 건삼, 백삼, 홍삼, 흑삼 등으로 나눌 수 있다. 수삼을 껍질을 제거하지 않고 그대로 건조한 것을 건삼이라 하며, 수삼의 껍질을 제거한 후 건조한 삼을 백삼이라 한다. 수삼을 증기로 쪄서 건조시키는 증숙 및 건조 단계를 거쳐 얻는 것을 홍삼이라 한다. 흑삼은 홍삼의 특유한 형태로 한번의 증숙과 건조과정을 거쳐 제조되는 일반 홍삼과 달리 통상적으로 아홉번 찌고 말리는 구증구포 방법으로 제조된다. 2012년 1월 개정된 인삼산업법 시행규칙에 의하면, 흑삼은 수삼을 증기나 그 밖의 방법으로 쪄서 익혀 말린 것으로서 담흑갈색 또는 흑다갈색을 띠는 것으로, 제조 기준에 의하면 증숙과 건조 과정이 3회 이상 반복된 것을 지칭한다. 하기 본 명세서에서 특별한 언급이 없는 한 홍삼은 일회의 증숙과정 만을 거친 홍삼뿐 아니라 반복된 증숙 및 건조과정을 거친 흑삼을 포함한 포괄된 용어로 사용한다. 홍삼은 가공에 의해 저장성이 향상될 뿐 아니라, 가열 및 가수분해 과정을 거치면서 수삼에는 존재하지 않는 홍삼 특유의 사포닌이 형성되어 고유한 약리효과를 갖게 된다.Ginseng as it is harvested from the field is called fresh ginseng, and because fresh ginseng contains about 70% moisture, it is easy to be damaged during storage or distribution, so it improves storability by processing. Ginseng can be divided into dried ginseng, white ginseng, red ginseng, and black ginseng according to the processing method. Dry ginseng is called dried ginseng without removing the skin, and white ginseng is dried after removing the skin of fresh ginseng. Red ginseng is obtained by steaming and drying fresh ginseng with steam. Black ginseng is a unique form of red ginseng, and unlike general red ginseng, which is manufactured through one steaming and drying process, it is usually manufactured by steaming and drying nine times. According to the Enforcement Regulations of the Ginseng Industry Act revised in January 2012, black ginseng is fresh ginseng steamed or dried by steaming or other methods and has a light dark brown or dark dark brown color. refers to repetition. In the present specification, unless otherwise specified, red ginseng is used as an encompassing term including red ginseng that has undergone only one steaming process as well as black ginseng that has undergone repeated steaming and drying processes. Red ginseng not only has improved storage properties by processing, but also has unique pharmacological effects by forming saponins unique to red ginseng that do not exist in fresh ginseng through heating and hydrolysis.
상술한 인삼의 주요 활성성분은 진세노사이드사포닌)이다. 진세노사이드류 화합물은 3가지 유형으로 나눌 수 있다. 먼저 한 종류는 올레안난 (Oleanane)형 Pentacyclic Triterpene 사포닌으로 sapogenin은 Oleanonic acid이고 다른 두 종류는 Dammarane형의 Tetracyclic triterpene saponin: protopanoxadiol (PPD)와Protopanaxatriol (PPT) 이다. 프로토파나사디올 (Protopanaxadiol)류 사포닌은 Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rg5, Rh2, Rh3, F2, C-K 등을 포함하고 프로토파나사트리올 (Protopanaxatriol) 류 사포닌은Ginsenoside Re, Rf, Rg1, Rg2, Rg4, Rh1, Rh4등이다.The main active ingredient of ginseng mentioned above is ginsenoside saponin). Ginsenoside compounds can be divided into three types. First, one type is an oleanane type pentacyclic triterpene saponin, the sapogenin is Oleanonic acid, and the other two types are the Dammarane type tetracyclic triterpene saponin: protopanoxadiol (PPD) and Protopanaxatriol (PPT). Protopanaxadiol type saponins include Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rg5, Rh2, Rh3, F2, C-K, etc., and Protopanaxatriol type Saponins are Ginsenoside Re, Rf, Rg1, Rg2, Rg4, Rh1, Rh4, etc.
비록 Ginsenoside (사포닌)의 종류가 40여종에 달하지만 오직 Rg3, Rg5, Rh2, Rh3등 희유 사포닌 및 Rg2, Rg4, Rh1, Rh4 등 활성이 높은 사포닌만이 더욱 가치가 있다. 예를 들어 Rh2(Rh3 포함)은 항암, 암세포 사멸, 항혈전, 항암제 내성방지, 면역력을 증가시키고 Rh1(Rh4 포함) 은 항암, 간장보호, 항유리기 작용이 있으며; Rg3(Rg5 포함) 은 항혈전, 항암, 기억력 제고, 항유리기 작용이 있으며; Rg2(Rg4 포함) 은 심장보호, 기억력 향상, 항혈전, 항유리기 작용이 있다.Although there are more than 40 types of ginsenoside (saponin), only rare saponins such as Rg3, Rg5, Rh2, and Rh3 and saponins with high activity such as Rg2, Rg4, Rh1, and Rh4 are more valuable. For example, Rh2 (including Rh3) has anti-cancer, cancer cell death, anti-thrombosis, anti-cancer drug resistance, and increases immunity, and Rh1 (including Rh4) has anti-cancer, hepatoprotective, and anti-free radical action; Rg3 (including Rg5) has antithrombotic, anticancer, memory-enhancing, anti-free radical action; Rg2 (including Rg4) has cardioprotection, memory improvement, antithrombotic, and antifree radical action.
따라서, 상기한 희유 사포닌 및 활성이 높은 사포닌의 함량이 높은 홍삼을 제조하기 위해 다양한 연구가 개시되어 있다. 이와 관련하여, 한국등록특허공보 제 10-1435706호는 증숙한 삼을 진공건조하여 홍삼 사포닌의 함량을 강화하는 사포닌 강화 홍삼의 제조방법에 대해 개시하고 있으며, 한국등록특허공보 제 10-1233991호는 발효과정을 통해 희유 사포닌의 함량을 증가시킨 발효홍삼의 제조방법에 대해 개시하고 있다.Therefore, various studies have been disclosed to prepare red ginseng having a high content of the rare saponins and saponins with high activity. In this regard, Korea Patent Publication No. 10-1435706 discloses a manufacturing method of saponin-enhanced red ginseng that enhances the content of red ginseng saponin by vacuum drying steamed ginseng, and Korean Patent Publication No. 10-1233991 discloses Disclosed is a method for producing fermented red ginseng in which the content of rare saponins is increased through the fermentation process.
그러나, 희유 사포닌의 함량을 증가시키는 과정은 꾸준히 연구가 진행되어야 하는 상황이며 제조과정에서 시간이 많이 걸리거나 홍삼 제조 과정에서 불량률이 생기는 등의 제조 수율의 문제점이 생겨 더욱 연구가 필요한 상황이다.However, the process of increasing the content of rare saponins is a situation that requires continuous research, and there are problems in manufacturing yield, such as taking a lot of time in the manufacturing process or defective rate in the red ginseng manufacturing process, so further research is needed.
상기와 같은 문제를 해결하기 위해, 본 발명은 혼합 숙성액을 이용하여 홍삼의 제조에 필요한 증숙 및 건조 시간을 단축시키는 동시에 불량 홍삼을 줄여 수율을 높이고 유효성분인 진세노사이드의 함량을 증가시킨 유효성분 및 수율이 개선된 홍삼의 제조방법을 제공한다.In order to solve the above problems, the present invention reduces the steaming and drying time required for the production of red ginseng by using a mixed aged liquid, and at the same time reduces the defective red ginseng to increase the yield and increase the content of the active ingredient ginsenoside. Provided is a method for producing red ginseng with improved ingredients and yield.
상기 목적은 아피오스 추출물, 녹차 추출물, 파인애플 추출물 및 은행잎 추출물로 구성되는 혼합 숙성액을 제조하는 단계; 수삼을 상기 혼합 숙성액에 침지하고 2~4일간 1차 숙성하는 단계; 숙성된 수삼을 70~75℃에서 5분, 75~80℃에서 5분, 80~85℃에서 15분, 85~90℃에서 35분 동안 증숙하는 1차 증숙 단계; 상기 1차 증숙된 수삼을 60~70℃에서 열풍건조하는 1차 건조 단계; 상기 1차 건조된 수삼에 혼합 숙성액을 스프레이 도포 후 10~30분간 숙성하는 2차 숙성 단계; 상기 2차 숙성된 수삼을 0.5MPa의 압력으로 80~90℃에서 1~3시간 동안 증숙하는 2차 증숙 단계; 및 상기 2차 증숙된 수삼을 60~70℃에서 열풍건조하는 2차 건조 단계; 를 포함하는 것인, 유효성분 및 수율이 개선된 홍삼의 제조방법에 의해 달성될 수 있다.The above object is to prepare a mixed aged liquid consisting of apios extract, green tea extract, pineapple extract and ginkgo leaf extract; Immersion of fresh ginseng in the mixed aging solution and primary aging for 2 to 4 days; The first steaming step of steaming aged fresh ginseng at 70~75℃ for 5 minutes, at 75~80℃ for 5 minutes, at 80~85℃ for 15 minutes, and at 85~90℃ for 35 minutes; A first drying step of hot air drying the first steamed fresh ginseng at 60 ~ 70 ℃; Secondary aging step of aging 10 to 30 minutes after spray application of the mixed aged liquid to the first dried fresh ginseng; a second steaming step of steaming the second-aged fresh ginseng at a pressure of 0.5 MPa at 80-90° C. for 1 to 3 hours; And a second drying step of hot air drying the second steamed fresh ginseng at 60 ~ 70 ℃; It can be achieved by a method for producing red ginseng with improved active ingredient and yield, which comprises a.
구체적으로, 상기 2차 숙성 단계는 혼합 숙성액 스프레이 도포 후 수삼의 표면에 콩가루를 도포하는 단계를 추가로 포함하는 것일 수 있다.Specifically, the second aging step may further include the step of applying soybean powder to the surface of fresh ginseng after spray application of the mixed aging liquid.
구체적으로, 상기 혼합 숙성액의 혼합 비율은 아피오스 추출물 50중량%, 녹차 추출물 20중량%, 파인애플 추출물 15중량% 및 은행잎 추출물 15중량%로 구성되는 것일 수 있다.Specifically, the mixing ratio of the mixed aged liquid may be composed of 50% by weight of apios extract, 20% by weight of green tea extract, 15% by weight of pineapple extract and 15% by weight of ginkgo leaf extract.
구체적으로, 상기 2차 건조 단계는 열풍건조 전 2차 증숙된 수삼에 혼합 숙성액을 스프레이 도포 후 10~30분간 숙성하는 3차 숙성 단계를 추가로 포함하는 것일 수 있다.Specifically, the secondary drying step may further include a tertiary aging step of aging 10 to 30 minutes after spray application of a mixed aged liquid to fresh ginseng that has been secondarily steamed before hot air drying.
상기 목적은 상기한 제조방법으로 제조된 유효성분 및 수율이 개선된 홍삼에 의해 달성될 수 있다.The above object can be achieved by the red ginseng with an improved yield and an active ingredient prepared by the above-mentioned manufacturing method.
본 발명에 따른 유효성분 및 수율이 개선된 홍삼은 혼합 숙성액을 이용하여 홍삼의 제조에 필요한 증숙 및 건조 시간을 단축시키는 동시에 불량 홍삼을 줄여 수율을 높이고 유효성분인 진세노사이드의 함량을 증가시켰기에 홍삼의 약리활성을 이용하는 다양한 분야에 사용이 가능하다.Red ginseng with improved active ingredient and yield according to the present invention uses a mixed aged liquid to shorten the steaming and drying time required for the production of red ginseng, while reducing defective red ginseng to increase yield and increase the content of active ingredient ginsenoside. It can be used in various fields using the pharmacological activity of red ginseng.
도 1은 일실시예에 따른 유효성분 및 수율이 개선된 홍삼의 제조방법을 설명하기 위한 흐름도이다.1 is a flowchart for explaining a method of manufacturing red ginseng with improved active ingredient and yield according to an embodiment.
이하에서, 첨부된 도면을 참조하여 실시예들을 상세하게 설명한다. 그러나, 실시예들에는 다양한 변경이 가해질 수 있어서 특허출원의 권리 범위가 이러한 실시예들에 의해 제한되거나 한정되는 것은 아니다. 실시예들에 대한 모든 변경, 균등물 내지 대체물이 권리 범위에 포함되는 것으로 이해되어야 한다.Hereinafter, embodiments will be described in detail with reference to the accompanying drawings. However, since various changes may be made to the embodiments, the scope of the patent application is not limited or limited by these embodiments. It should be understood that all modifications, equivalents and substitutes for the embodiments are included in the scope of the rights.
실시예들에 대한 특정한 구조적 또는 기능적 설명들은 단지 예시를 위한 목적으로 개시된 것으로서, 다양한 형태로 변경되어 실시될 수 있다. 따라서, 실시예들은 특정한 개시형태로 한정되는 것이 아니며, 본 명세서의 범위는 기술적 사상에 포함되는 변경, 균등물, 또는 대체물을 포함한다.Specific structural or functional descriptions of the embodiments are disclosed for purposes of illustration only, and may be changed and implemented in various forms. Accordingly, the embodiments are not limited to a specific disclosure form, and the scope of the present specification includes changes, equivalents, or substitutes included in the technical spirit.
제1 또는 제2 등의 용어를 다양한 구성요소들을 설명하는데 사용될 수 있지만, 이런 용어들은 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 해석되어야 한다. 예를 들어, 제1 구성요소는 제2 구성요소로 명명될 수 있고, 유사하게 제2 구성요소는 제1 구성요소로도 명명될 수 있다.Although terms such as first or second may be used to describe various elements, these terms should be interpreted only for the purpose of distinguishing one element from another. For example, a first component may be termed a second component, and similarly, a second component may also be termed a first component.
어떤 구성요소가 다른 구성요소에 "연결되어" 있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결되어 있거나 또는 접속되어 있을 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다.When a component is referred to as being “connected” to another component, it may be directly connected or connected to the other component, but it should be understood that another component may exist in between.
실시예에서 사용한 용어는 단지 설명을 목적으로 사용된 것으로, 한정하려는 의도로 해석되어서는 안된다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 명세서에서, "포함하다" 또는 "가지다" 등의 용어는 명세서 상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.Terms used in the examples are used for the purpose of description only, and should not be construed as limiting. The singular expression includes the plural expression unless the context clearly dictates otherwise. In the present specification, terms such as “comprise” or “have” are intended to designate that a feature, number, step, operation, component, part, or combination thereof described in the specification exists, but one or more other features It is to be understood that this does not preclude the possibility of the presence or addition of numbers, steps, operations, components, parts, or combinations thereof.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 실시예가 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 첨부되는 도면과 함께 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described below in detail in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, only these embodiments allow the disclosure of the present invention to be complete, and common knowledge in the technical field to which the present invention belongs It is provided to fully inform the possessor of the scope of the invention, and the present invention is only defined by the scope of the claims.
본 발명의 실시예들에서, 별도로 다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 발명의 실시예에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.In the embodiments of the present invention, unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs. have meaning Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in an embodiment of the present invention, an ideal or excessively formal meaning is not interpreted as
본 발명의 실시예를 설명하기 위한 도면에 개시된 형상, 크기, 비율, 각도, 개수 등은 예시적인 것이므로 본 발명이 도시된 사항에 한정되는 것은 아니다. 또한, 본 발명을 설명함에 있어서, 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우 그 상세한 설명은 생략한다. 본 명세서 상에서 언급된 '포함한다', '갖는다', '이루어진다' 등이 사용되는 경우 '~만'이 사용되지 않는 이상 다른 부분이 추가될 수 있다. 구성 요소를 단수로 표현한 경우에 특별히 명시적인 기재 사항이 없는 한 복수를 포함하는 경우를 포함한다.The shapes, sizes, proportions, angles, numbers, etc. disclosed in the drawings for explaining the embodiments of the present invention are illustrative and the present invention is not limited to the illustrated matters. In addition, in describing the present invention, if it is determined that a detailed description of a related known technology may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be omitted. When 'including', 'having', 'consisting', etc. mentioned in this specification are used, other parts may be added unless 'only' is used. When a component is expressed in the singular, the case in which the plural is included is included unless specifically stated otherwise.
구성 요소를 해석함에 있어서, 별도의 명시적 기재가 없더라도 오차 범위를 포함하는 것으로 해석한다.In interpreting the components, it is interpreted as including an error range even if there is no separate explicit description.
도면에서 나타난 각 구성의 크기 및 두께는 설명의 편의를 위해 도시된 것이며, 본 발명이 도시된 구성의 크기 및 두께에 반드시 한정되는 것은 아니다.The size and thickness of each component shown in the drawings are illustrated for convenience of description, and the present invention is not necessarily limited to the size and thickness of the illustrated component.
본 발명의 여러 실시예들의 각각 특징들이 부분적으로 또는 전체적으로 서로 결합 또는 조합 가능하며, 당업자가 충분히 이해할 수 있듯이 기술적으로 다양한 연동 및 구동이 가능하며, 각 실시예들이 서로에 대하여 독립적으로 실시 가능할 수도 있고 연관 관계로 함께 실시 가능할 수도 있다.Each feature of the various embodiments of the present invention may be partially or wholly combined or combined with each other, and as those skilled in the art will fully understand, technically various interlocking and driving are possible, and each embodiment may be independently implemented with respect to each other. It may be possible to implement together in a related relationship.
본원의 일 측면은, 아피오스 추출물, 녹차 추출물, 파인애플 추출물 및 은행잎 추출물로 구성되는 혼합 숙성액을 제조하는 단계; 수삼을 상기 혼합 숙성액에 침지하고 2~4일간 1차 숙성하는 단계; 숙성된 수삼을 70~75℃에서 5분, 75~80℃에서 5분, 80~85℃에서 15분, 85~90℃에서 35분 동안 증숙하는 1차 증숙 단계; 상기 1차 증숙된 수삼을 60~70℃에서 열풍건조하는 1차 건조 단계; 상기 1차 건조된 수삼에 혼합 숙성액을 스프레이 도포 후 10~30분간 숙성하는 2차 숙성 단계; 상기 2차 숙성된 수삼을 0.5MPa의 압력으로 80~90℃에서 1~3시간 동안 증숙하는 2차 증숙 단계; 및 상기 2차 증숙된 수삼을 60~70℃에서 열풍건조하는 2차 건조 단계; 를 포함하는 것인, 유효성분 및 수율이 개선된 홍삼의 제조방법을 제공한다.One aspect of the present application, comprising the steps of preparing a mixed aged liquid consisting of apios extract, green tea extract, pineapple extract and ginkgo leaf extract; Immersion of fresh ginseng in the mixed aging solution and primary aging for 2 to 4 days; The first steaming step of steaming aged fresh ginseng at 70~75℃ for 5 minutes, at 75~80℃ for 5 minutes, at 80~85℃ for 15 minutes, and at 85~90℃ for 35 minutes; A first drying step of hot air drying the first steamed fresh ginseng at 60 ~ 70 ℃; Secondary aging step of aging 10 to 30 minutes after spray application of the mixed aged liquid to the first dried fresh ginseng; a second steaming step of steaming the second-aged fresh ginseng at a pressure of 0.5 MPa at 80-90° C. for 1 to 3 hours; And a second drying step of hot air drying the second steamed fresh ginseng at 60 ~ 70 ℃; It provides a method for producing red ginseng with improved active ingredient and yield, comprising a.
이하, 도 1을 통해 본 발명의 일 실시예에 따른 유효성분 및 수율이 개선된 홍삼의 제조방법을 설명할 수 있다.Hereinafter, a method for producing red ginseng with improved active ingredient and yield according to an embodiment of the present invention can be described with reference to FIG. 1 .
먼저, 아피오스 추출물, 녹차 추출물, 파인애플 추출물 및 은행잎 추출물로 구성되는 혼합 숙성액을 제조한다.First, a mixed aged liquid consisting of an apios extract, a green tea extract, a pineapple extract, and a ginkgo leaf extract is prepared.
상기 아피오스(Apios americana)는 콩과 아피오스속의 여러해살이 덩굴식물이며, 인디언감자로도 불린다. 아피오스는 사포닌과 강력한 항산화 성분인 비타민 E, 베타카로틴이 풍부하여 면역력 강화에 탁월하며, 노화를 촉진하는 체내 활성산소를 제거해 피부 미용에도 효과적이다.The Apios (Apios americana) is a perennial vine of the genus Apios in the legume family, and is also called Indian potato. Apios is rich in saponins and powerful antioxidants such as vitamin E and beta-carotene, so it is excellent for strengthening immunity.
상기 녹차는 차나무의 어린잎을 수확하여 발효시키지 않고 푸른 빛이 그대로 나도록 말린 찻잎 또는 찻잎을 우린 물을 의미한다. 폴리페놀의 일종인 카테킨이라는 성분이 있어 체지방 연소에 도움을 줄 수 있으며, 노화 유발의 주 원인인 활성 산소를 잡아 노화 방지와 심혈관계와 신진대사에도 긍정적인 영향을 줄 수 있다.The green tea refers to dried tea leaves or water obtained by brewing tea leaves so that the young leaves of the tea tree are harvested and not fermented to give a blue light. Catechin, a type of polyphenol, can help burn body fat, and it can have a positive effect on the cardiovascular system and metabolism by catching active oxygen, which is the main cause of aging.
상기 파인애플(Pineapple, Ananas comosus)은 파인애플속 파인애플과의 여러해살이풀이며, 주로 열매를 생으로 먹거나 통조림, 주스, 샐러드 과자 등으로 가공하여 섭취한다. 브로멜라인 효소가 풍부하여 혈액 응고를 방지하고 소염 효과를 일으켜 급성 축농증, 인후염, 관절염, 통풍과 같은 염증성 질환을 치료하는데 효과가 있다. 또한 비타민 C, 요오드, 마그네슘, 인, 칼슘과 같은 항산화 성분이 풍부하여 면역력을 증강시키고 체내 활성 산소를 막아 동맥 경화, 심장 질환, 당뇨, 항암에도 도움이 된다.The pineapple (Pineapple, Ananas comosus) is a perennial plant of the pineapple family of the genus Pineapple, and is mainly consumed by eating the fruit raw or processing it into canned food, juice, salad snack, etc. Since it is rich in bromelain enzyme, it prevents blood clotting and has an anti-inflammatory effect, which is effective in treating inflammatory diseases such as acute sinusitis, sore throat, arthritis, and gout. In addition, it is rich in antioxidants such as vitamin C, iodine, magnesium, phosphorus, and calcium, which enhances immunity and blocks free radicals in the body, which is helpful for arteriosclerosis, heart disease, diabetes, and cancer.
상기 은행잎은 은행나무과의 낙엽교목인 은행나무의 잎을 의미한다. 상기 은행잎 추출물은 항균, 항암, 항바이러스, 항알레르기 및 항염증 활성을 가져 다양한 분야에서 활용될 수 있다.The ginkgo leaf refers to a leaf of a ginkgo tree, a deciduous tree of the ginkgo family. The ginkgo leaf extract has antibacterial, anticancer, antiviral, antiallergic and anti-inflammatory activity and can be utilized in various fields.
상기 추출물은 목적하는 물질을 다양한 용매에 침지한 다음, 상온 또는 가온상태에서 일정시간 동안 추출하여 수득한 액상성분, 상기 액상성분으로부터 용매를 제거하여 수득한 고형분 등의 결과물을 의미할 수 있다. 뿐만 아니라, 상기 결과물에 더하여, 상기 결과물의 희석액, 이들의 농축액, 이들의 조정제물, 정제물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있다.The extract may refer to a resultant such as a liquid component obtained by immersing a target substance in various solvents and then extracting for a predetermined time at room temperature or a warm state, a solid obtained by removing the solvent from the liquid component, and the like. In addition, in addition to the result, it can be comprehensively interpreted as including all of the dilutions of the results, their concentrates, their preparations, and their purified products.
상기 추출물을 수득하기 위한 방법은 특별히 이에 제한되지 않으나, 바람직하게는 상기 식물의 뿌리, 줄기, 잎, 열매, 꽃, 이들의 건조물, 가공물 등을 용매에 침지하고, 10 내지 25℃의 상온에서 추출하는 냉침추출법, 40 내지 100℃로 가열하여 추출하는 가열추출법, 초음파를 가하여 추출하는 초음파추출법, 환류냉각기를 이용한 환류추출법 등의 방법을 사용할 수 있다.The method for obtaining the extract is not particularly limited thereto, but preferably the roots, stems, leaves, fruits, flowers, dried products thereof, processed products, etc. of the plants are immersed in a solvent, and extracted at room temperature of 10 to 25° C. Methods such as cold extraction method, heating extraction method by heating to 40 to 100 ℃, ultrasonic extraction method extraction by adding ultrasonic waves, reflux extraction method using a reflux condenser can be used.
일 실시예에 있어서, 상기 혼합 숙성액의 혼합 비율은 아피오스 추출물 50중량%, 녹차 추출물 20중량%, 파인애플 추출물 15중량% 및 은행잎 추출물 15중량%로 구성되는 것일 수 있다.In one embodiment, the mixing ratio of the mixed aged liquid may be composed of 50% by weight of apios extract, 20% by weight of green tea extract, 15% by weight of pineapple extract and 15% by weight of ginkgo leaf extract.
다음으로, 수삼을 상기 혼합 숙성액에 침지하고 2~4일간 1차 숙성한다.Next, fresh ginseng is immersed in the mixed aged solution and first aged for 2 to 4 days.
상기 수삼은 두릅나무과에 속하는 여러해살이풀인 인삼(Panax ginseng)의 뿌리를 말리지 않은 상태 그대로 둔 것을 의미한다. 인삼은 강장제 역할에 의한 신체의 항상성 유지, 학습기능 증진과 기억력감퇴 개선 및 지적작업 수행효율 향상, 통증완화작용, 암 예방 효능(암세포의 증식 및 전이 억제, 항암제의 항암활성 증강), 항당뇨 효능, 간기능 항진, 혈압 조절 외에 항피로및 항스트레스, AIDS바이러스(HIV) 증식억제, 여성갱년기 장애 및 남성 성기능 장애 개선, 항산화 활성 및 노화억제 효능 등이 있는 것으로 알려져 있으며, 인삼의 주요 활성성분은 사포닌(saponin) 또는 진세노사이드(ginsenosides)라는 복합 탄수화물 (알코올 또는 페놀과 당의 복합체)로 알려져 있다.The fresh ginseng means that the root of ginseng (Panax ginseng), which is a perennial plant belonging to the family Araliaceae, is left in an undried state. Ginseng maintains body homeostasis by acting as a tonic agent, improves learning function, improves memory decline, and improves intellectual task performance, pain relief, cancer prevention effect (inhibition of cancer cell proliferation and metastasis, anticancer activity enhancement), antidiabetic effect It is known to have anti-fatigue and anti-stress, AIDS virus (HIV) proliferation inhibition, improvement of female menopausal disorders and male sexual dysfunction, antioxidant activity and anti-aging effect, in addition to liver function improvement and blood pressure control. Complex carbohydrates (complexes of alcohol or phenol and sugar) are known as saponins or ginsenosides.
본 발명에서의 혼합 숙성액은 수삼의 조직에 흡수되어 숙성 과정을 통해 수삼의 성분과 혼합 숙성액의 성분이 시너지를 일으켜 수삼의 활성성분을 증가시키는 것일 수 있다.The mixed aged liquid in the present invention may be absorbed into the tissues of fresh ginseng and increase the active ingredients of fresh ginseng by synergizing the components of the fresh ginseng and the components of the mixed aged liquid through the aging process.
침지 기간이 2일 미만일 경우 혼합 숙성액의 성분이 수삼에 충분히 침투되지 않고 숙성이 부족해질 수 있으며, 침지 기간이 4일 초과일 경우 숙성이 지나쳐 생성된 수삼의 활성성분이 혼합 숙성액에 용해될 수 있다.If the immersion period is less than 2 days, the components of the mixed aged liquid may not penetrate sufficiently into the fresh ginseng and ripening may be insufficient. can
다음으로, 숙성된 수삼을 70~75℃에서 5분, 75~80℃에서 5분, 80~85℃에서 15분, 85~90℃에서 35분 동안 증숙한다.Next, the aged fresh ginseng is steamed at 70~75℃ for 5 minutes, at 75~80℃ for 5 minutes, at 80~85℃ for 15 minutes, and at 85~90℃ for 35 minutes.
본 발명에서의 1차 증숙 시간은 수삼의 활성성분을 짧은 시간에 증가시킬 수 있도록 수삼 증숙의 최대 효율을 위해 설정된 시간이며 2차 숙성 단계의 숙성을 원활하게 돕기 위한 과정일 수 있다.The first steaming time in the present invention is a time set for maximum efficiency of fresh ginseng steaming so that the active ingredients of fresh ginseng can be increased in a short time, and may be a process to help the ripening of the second ripening step smoothly.
다음으로, 상기 1차 증숙된 수삼을 60~70℃에서 열풍건조한다.Next, the first steamed fresh ginseng is dried in hot air at 60 ~ 70 ℃.
본 발명에서 1차 증숙된 수삼을 열풍건조하는 과정은 수삼의 유효성분을 응축시키는 과정인 동시에 수삼의 조직 내 공간을 만들어 2차 숙성시의 혼합 숙성액 침투를 원활하게 만드는 것일 수 있다.In the present invention, the process of hot air drying of the first steamed fresh ginseng may be a process of condensing the active ingredients of the fresh ginseng, and at the same time creating a space in the tissue of the fresh ginseng to facilitate penetration of the mixed aged liquid during secondary ripening.
다음으로, 상기 1차 건조된 수삼에 혼합 숙성액을 스프레이 도포 후 10~30분간 숙성한다.Next, after spray application of the mixed aged liquid to the first dried fresh ginseng, it is aged for 10 to 30 minutes.
일 실시예에 있어서, 상기 2차 숙성 단계는 혼합 숙성액 스프레이 도포 후 수삼의 표면에 콩가루를 도포하는 단계를 추가로 포함하는 것일 수 있다.In one embodiment, the secondary ripening step may further include applying soybean powder to the surface of fresh ginseng after spray application of the mixed aging liquid.
다음으로, 상기 2차 숙성된 수삼을 0.5MPa의 압력으로 80~90℃에서 1~3시간 동안 증숙한다.Next, the second-aged fresh ginseng is steamed for 1 to 3 hours at 80-90° C. at a pressure of 0.5 MPa.
본 발명에서 압력을 주어 수삼을 증숙하는 과정은 증숙 시간을 단축하여 증숙 효율을 증가시키는 것인 동시에 혼합 숙성액의 숙성 효과를 증진시키는 것일 수 있다.In the present invention, the process of steaming fresh ginseng by applying pressure may shorten the steaming time to increase the steaming efficiency and at the same time enhance the aging effect of the mixed aged liquid.
마지막으로, 상기 2차 증숙된 수삼을 60~70℃에서 열풍건조하여 홍삼을 제조한다.Finally, red ginseng is prepared by drying the second steamed fresh ginseng with hot air at 60-70°C.
일 실시예에 있어서, 상기 건조 단계는 2차 증숙된 수삼을 열풍건조하기 전 2차 증숙된 수삼에 혼합 숙성액을 스프레이 도포 후 10~30분간 숙성하는 3차 숙성 단계를 추가로 포함하는 것일 수 있다.In one embodiment, the drying step may further include a tertiary aging step of maturing for 10 to 30 minutes after spray application of a mixed aged liquid to the second steamed fresh ginseng before hot air drying of the second steamed fresh ginseng. have.
본원의 다른 일 측면은 상기 제조방법으로 제조된 유효성분 및 수율이 개선된 홍삼을 제공한다.Another aspect of the present application provides red ginseng with an improved yield and an active ingredient prepared by the above manufacturing method.
이하, 구체적인 실시예와 비교예를 통하여 본 발명의 구성 및 그에 따른 효과를 보다 상세히 설명하고자 한다. 그러나, 본 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것이며, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the configuration of the present invention and its effects will be described in more detail through specific examples and comparative examples. However, these examples are for explaining the present invention in more detail, and the scope of the present invention is not limited to these examples.
[실시예 1][Example 1]
먼저, 아피오스 추출물 50중량%, 녹차 추출물 20중량%, 파인애플 추출물 15중량% 및 은행잎 추출물 15중량%로 구성된 혼합 숙성액을 제조하였다. 제조된 혼합 숙성액을 숙성용 수조에 채운 다음 수삼을 침지한 후 3일간 숙성시켰다.First, a mixed aged liquid consisting of 50% by weight of apios extract, 20% by weight of green tea extract, 15% by weight of pineapple extract and 15% by weight of ginkgo leaf extract was prepared. The prepared mixed aging liquid was filled in a water bath for aging, and then fresh ginseng was immersed and aged for 3 days.
다음으로, 숙성된 수삼을 증숙기를 이용하여 72℃에서 5분, 79℃에서 5분, 80℃에서 15분, 90℃에서 35분 동안 증숙시켰다. 증숙된 수삼을 70℃에서 열풍건조한 후 건조된 수삼에 혼합 숙성액을 스프레이 도포 후 30분간 2차 숙성하였다.Next, the aged fresh ginseng was steamed for 5 minutes at 72°C, 5 minutes at 79°C, 15 minutes at 80°C, and 35 minutes at 90°C using a steamer. After the steamed fresh ginseng was dried by hot air at 70°C, the mixed aged ginseng solution was spray applied to the dried fresh ginseng, followed by secondary aging for 30 minutes.
마지막으로, 2차 숙성이 끝난 수삼을 0.5MPa의 압력으로 90℃에서 2시간 동안 2차 증숙한 다음 증숙이 끝난 수삼을 70℃에서 열풍건조하여 홍삼을 수득하였다. 제조된 홍삼을 실시예 1로 명명하였다.Finally, red ginseng was obtained by secondly steaming the fresh ginseng after secondary aging at a pressure of 0.5 MPa at 90° C. for 2 hours, and then drying the steamed fresh ginseng with hot air at 70° C. The prepared red ginseng was named Example 1.
[실시예 2][Example 2]
실시예 1과 동일한 방법으로 제조하되, 2차 숙성 단계에서 혼합 숙성액 스프레이 도포 후 수삼의 표면에 콩가루를 도포하는 단계를 추가로 포함하여 제조된 홍삼을 실시예 2로 명명하였다.Red ginseng prepared in the same manner as in Example 1, but further comprising the step of applying soybean powder to the surface of fresh ginseng after spray application of the mixed aged solution in the second ripening step, was named as Example 2.
[실시예 3][Example 3]
실시예 1과 동일한 방법으로 제조하되, 열풍건조 전 2차 증숙된 수삼에 혼합 숙성액을 스프레이 도포 후 10~30분간 숙성하는 3차 숙성 단계를 추가로 포함하여 제조된 홍삼을 실시예 3으로 명명하였다.Red ginseng prepared in the same manner as in Example 1, but further including a third aging step of aging for 10 to 30 minutes after spray application of a mixed aged liquid to fresh ginseng that had been secondarily steamed before hot air drying, was named as Example 3. did.
[비교예 1][Comparative Example 1]
실시예 1과 동일한 방법으로 제조하되, 숙성과정에서 사용되는 혼합 숙성액을 물로 대 체여 제조된 홍삼을 비교예 1로 명명하였다.Red ginseng prepared in the same manner as in Example 1, except that the mixed aged liquid used in the aging process was replaced with water, was named as Comparative Example 1.
[비교예 2][Comparative Example 2]
종래에 알려진 홍삼 제조방법에 따라 4년근 홍삼을 95℃에서 1시간 증숙한 다음 65℃에서 72시간 동안 열풍건조하여 제조된 홍삼을 비교예 2로 명명하였다.Red ginseng prepared by steaming 4-year-old red ginseng at 95° C. for 1 hour according to a conventionally known red ginseng production method and then drying it with hot air at 65° C. for 72 hours was named Comparative Example 2.
[실험예 1: 진세노사이드 함량 비교][Experimental Example 1: Comparison of ginsenoside content]
상기 실시예 1내지 3과 비교예 1 및 2의 홍삼을 각각 75% 주정(25% 물)으로 추출원물의 8배 가수(w/w)하여 55~65 ℃에서 10 시간 동안 추출한 다음, 65브릭스(Brix)가 되도록 40~45℃에서 각각 농축하였다.The red ginseng of Examples 1 to 3 and Comparative Examples 1 and 2 were respectively hydrolyzed (w/w) 8 times with 75% alcohol (25% water), extracted at 55 to 65 ° C. for 10 hours, and then 65 Brix. (Brix) was concentrated at 40 ~ 45 ℃, respectively.
HPLC 분석법을 통해 상기 농축한 홍삼액의 진세노사이드 함량을 분석하여 하기 표 1에 나타내었다.The ginsenoside content of the concentrated red ginseng solution was analyzed through HPLC analysis, and is shown in Table 1 below.
표 1에 나타낸 바와 같이, 비교예 1 및 2와 대비하여 실시예 1내지 3의 진세노사이드 함량이 전반적으로 높음을 확인하여 본 발명의 제조방법이 진세노사이드의 함량을 증가시켰음을 확인할 수 있었다. 특히 실시예 1과 비교하여 실시예 2는 진세노사이드 Rg3, Rk1 및 Rh2의 함량이 증가한 것을 확인할 수 있으며, 실시예 3은 진세노사이드 Rc, F2, Rk1 및 Rh2의 함량이 증가한 것을 확인할 수 있는데 진세노사이드 Rc, F2, Rk1 및 Rh2는 수삼에서는 거의 검출되지 않으며 가공을 진행한 홍삼에서만 검출되는 성분으로 본 발명에 따른 제조방법에서 혼합 숙성액에 의한 숙성과정이 진세노사이드 Rc, F2, Rk1 및 Rh2의 함량을 증가시키는 것으로 판단할 수 있다.As shown in Table 1, compared to Comparative Examples 1 and 2, it was confirmed that the ginsenoside content of Examples 1 to 3 was generally high, and it was confirmed that the production method of the present invention increased the ginsenoside content. . In particular, compared to Example 1, Example 2 can confirm that the content of ginsenoside Rg3, Rk1 and Rh2 is increased, Example 3 can confirm that the content of ginsenoside Rc, F2, Rk1 and Rh2 is increased. Ginsenosides Rc, F2, Rk1 and Rh2 are hardly detected in fresh ginseng, but are detected only in processed red ginseng. And it can be determined to increase the content of Rh2.
Claims (3)
수삼을 상기 혼합 숙성액에 침지하고 2~4일간 1차 숙성하는 단계;
숙성된 수삼을 70~75℃에서 5분, 75~80℃에서 5분, 80~85℃에서 15분, 85~90℃에서 35분 동안 증숙하는 1차 증숙 단계;
상기 1차 증숙된 수삼을 60~70℃에서 열풍건조하는 1차 건조 단계;
상기 1차 건조된 수삼에 혼합 숙성액을 스프레이 도포 후 수삼의 표면에 콩가루를 도포한 다음 10~30분간 숙성하는 2차 숙성 단계;
상기 2차 숙성된 수삼을 0.5MPa의 압력으로 80~90℃에서 1~3시간 동안 증숙하는 2차 증숙 단계; 및
상기 2차 증숙된 수삼을 60~70℃에서 열풍건조하는 2차 건조 단계; 를 포함하는 것인, 유효성분 및 수율이 개선된 홍삼의 제조방법.
Preparing a mixed aged liquid consisting of 50% by weight of apios extract, 20% by weight of green tea extract, 15% by weight of pineapple extract and 15% by weight of ginkgo leaf extract;
Immersion of fresh ginseng in the mixed aging solution and primary aging for 2 to 4 days;
The first steaming step of steaming aged fresh ginseng at 70~75℃ for 5 minutes, at 75~80℃ for 5 minutes, at 80~85℃ for 15 minutes, at 85~90℃ for 35 minutes;
A first drying step of hot air drying the first steamed fresh ginseng at 60 ~ 70 ℃;
A second aging step of spraying the mixed aging liquid on the first dried fresh ginseng and then applying soybean powder to the surface of the fresh ginseng and then aging for 10 to 30 minutes;
a second steaming step of steaming the second aged fresh ginseng at 80-90° C. for 1 to 3 hours at a pressure of 0.5 MPa; and
A second drying step of hot air drying the second steamed fresh ginseng at 60 ~ 70 ℃; A method of producing red ginseng with improved active ingredient and yield, comprising:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220087351A KR102458937B1 (en) | 2022-07-15 | 2022-07-15 | Method for producing red ginseng with improved active ingredients and yield |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220087351A KR102458937B1 (en) | 2022-07-15 | 2022-07-15 | Method for producing red ginseng with improved active ingredients and yield |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102458937B1 true KR102458937B1 (en) | 2022-10-25 |
Family
ID=83803973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220087351A KR102458937B1 (en) | 2022-07-15 | 2022-07-15 | Method for producing red ginseng with improved active ingredients and yield |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102458937B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102677837B1 (en) * | 2023-12-19 | 2024-06-24 | 주식회사 에스제이유글로벌 | Red ginseng with increased ginsenoside content and method for manufacturing the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060108268A (en) * | 2006-09-27 | 2006-10-17 | 주식회사 서울식연 | A making method an antioxidant from ginseng steamed red and antioxidant |
KR101233991B1 (en) | 2010-03-18 | 2013-02-18 | 동국대학교 산학협력단 | Manufacturing method of fermentative red ginseng |
KR101435706B1 (en) | 2011-12-08 | 2014-09-02 | 주식회사 풀무원 | Red ginseng containing improved saponin contents and process, use of the same |
KR101851369B1 (en) * | 2018-03-08 | 2018-04-23 | 장성기 | Manufacturing method of processed coffee beans using Black Ginseng process |
KR20200042325A (en) * | 2018-10-15 | 2020-04-23 | 농업회사법인 주식회사 함양산양삼 | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof |
KR20210059888A (en) * | 2019-11-18 | 2021-05-26 | 농업회사법인 (주)케이앤바이오 | Method of preparing black platycodon enhanced saponin contents, platycodon extract and liquid stick comprising the same |
-
2022
- 2022-07-15 KR KR1020220087351A patent/KR102458937B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060108268A (en) * | 2006-09-27 | 2006-10-17 | 주식회사 서울식연 | A making method an antioxidant from ginseng steamed red and antioxidant |
KR101233991B1 (en) | 2010-03-18 | 2013-02-18 | 동국대학교 산학협력단 | Manufacturing method of fermentative red ginseng |
KR101435706B1 (en) | 2011-12-08 | 2014-09-02 | 주식회사 풀무원 | Red ginseng containing improved saponin contents and process, use of the same |
KR101851369B1 (en) * | 2018-03-08 | 2018-04-23 | 장성기 | Manufacturing method of processed coffee beans using Black Ginseng process |
KR20200042325A (en) * | 2018-10-15 | 2020-04-23 | 농업회사법인 주식회사 함양산양삼 | Liquid composition for stick-type container comprising active mountain-cultivated ginseng extract having increased ginsenosides of human body absorption type, and preparation method thereof |
KR20210059888A (en) * | 2019-11-18 | 2021-05-26 | 농업회사법인 (주)케이앤바이오 | Method of preparing black platycodon enhanced saponin contents, platycodon extract and liquid stick comprising the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102677837B1 (en) * | 2023-12-19 | 2024-06-24 | 주식회사 에스제이유글로벌 | Red ginseng with increased ginsenoside content and method for manufacturing the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shahrajabian et al. | A review of ginseng species in different regions as a multipurpose herb in traditional Chinese medicine, modern herbology and pharmacological science | |
KR101050821B1 (en) | Fermented black-red ginseng and the method of preparing it and fermented bellflower and fermented ginger | |
CN111544461A (en) | Panax plant extract produced by microwave irradiation, method for producing the same, and composition containing the same | |
CN104946453A (en) | Preparation and use method of health drug wheat koji | |
KR102458937B1 (en) | Method for producing red ginseng with improved active ingredients and yield | |
Huang et al. | Recent progress on processing technologies, chemical components, and bioactivities of Chinese red ginseng, American red ginseng, and Korean red ginseng | |
KR20130099756A (en) | Fermentated and steamed ginseng and fermentation and steaming method for the same | |
KR101558530B1 (en) | A manufacturing method of anti-obesity functional tea comprising fermented ginseng leaf, nelumbo nucifera and camellia sinensis and the anti-obesity functional tea manufactured by the method | |
KR102497193B1 (en) | Food Composition Comprising Low-Glycosides Ginsenoside Using Hydroponically grown Ginseng Leaf | |
KR20190137403A (en) | Method of producing extract having enhanced contents of gensenoside Rg6, Rk3 and Rh4 from Panax ginseng leaf and use of the extract | |
Gafforov et al. | Ganoderma adspersum (Schulzer) Donk; Ganoderma applanatum (Pers.) Pat.; Ganoderma lucidum (Curtis) P. Karst.; Ganoderma resinaceum Boud.-GANODERMATACEAE | |
KR101683478B1 (en) | Method for producing fermented red ginseng with enhanced ginsenoside Rg3 content | |
KR101557728B1 (en) | A manufacturing method of anti-obesity functional tea comprising fermented ginseng leaf, eucommia ulmoides and camellia sinensis and the anti-obesity functional tea manufactured by the method | |
KR102295116B1 (en) | Manufacturing method of black ginseng to improve cognitive function and black ginseng manufactured by the method | |
KR102106018B1 (en) | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage | |
CN107647074A (en) | A kind of nourishing the stomach, stomach invigorating, the preparation method of dyspepsia hawthorn Chinese yam Hericium erinaceus pressed candy | |
KR20070054764A (en) | Manufacturing method of black rootlets of ginseng | |
KR102677837B1 (en) | Red ginseng with increased ginsenoside content and method for manufacturing the same | |
KR101224574B1 (en) | Manufacturing method of fermentative red ginseng | |
KR19980068379A (en) | Manufacturing method of cheonma-containing processed food | |
KR101233991B1 (en) | Manufacturing method of fermentative red ginseng | |
KR20210014972A (en) | Method for producing fermented red ginseng with enhanced specific ginsenoside content | |
KR101295549B1 (en) | Method for producing red ginseng powder with enhanced saponin content | |
KR102665525B1 (en) | The method and the extract of extracting ginsenosides from red ginseng or black ginseng, manufactured using ultra-high pressure treatment, using high-temperature and high-pressure water | |
KR20200132439A (en) | Method for Manufacturing Fermented Ginseng Tablet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |